News
Categories
Sign up
Featured Posts
Archive
- September 2020
- June 2020
- April 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- July 2019
- June 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- May 2018
- April 2018
- March 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- July 2017
- May 2017
- April 2017
- February 2017
- January 2017
Follow Us
An Israeli medical technology company is set to begin testing its new radiation cancer therapy in leading medical centers in Italy. The Alpha DaRT (Dіffusіng Alpha-emіtters Radіatіon Therapy) device delivers high-precision alpha radiation that is released when radioactive substances decay inside the tumor and kills cancer cells while sparing the surrounding healthy tissue, the company says. 3d illustration Cancer CellGETTY The company hopes to get approval from the European Commission by next year for the therapy. Early results from an ongoing clinical trial on 27 patients with squamous cell carcinoma (SCC) tumors at the Rabin Medical Center in Israel and the IRST (Istituto Scientifico Romag
Alpha Tau Medical Launches New Clinical Trials in Italy with Leading Cancer Centers, La Sapienza and
Trials will investigate the efficacy of its breakthrough cancer treatment, Alpha DaRT, in Squamous Cell Carcinoma (SCC) of the Skin, and Cutaneous and Mucosal malignant Neoplasia (CMN) TEL AVIV, Israel--(BUSINESS WIRE)--Alpha Tau Medical, developer of a breakthrough alpha-radiation cancer therapy, has announced the initiation of two new clinical trials evaluating the efficacy of the Alpha DaRT (Dіffusіng Alpha-emitters Radіatіon Therapy) with two leading medical centers in Rome, Italy. Following the approval from the Institutional Review Board (IRB), La Sapienza is initiating Alpha Tau’s clinical trial protocol for SCC of the Skin, and IFO is conducting their first study of Alpha DaRT for th
The Jewish New Year has now begun, providing us with a great opportunity to kick-off our quarterly Alpha Tau newsletter. This last year has seen fantastic progress. The significant operational, regulatory and clinical advancement was summarised by additional funding of $29 million that was recently raised from private and VC investors. Thank you to all our investors and partners – we cannot do this without you. We look forward to working together to realize the therapeutic potential of Alpha DaRT and develop a cancer treatment that can help save the lives of millions of patients around the world. I am delighted to share with you our latest news, developments and recent activities. E